[membership level=”0,4″][The content continues for paid members only.] Login or Subscribe [/membership][membership level=”1,5,6,7,8,9,10,11,12″][membership] FDA announced in the Federal Register in mid-April that it is seeking input from the pharmaceutical and biopharmaceutical industry for input on which industry experts should serve on 18 of its Center for Drug Evaluation and Research (CDER) advisory committees. The announcement noted that anyone interested in participating on the committees may nominate themselves. Committee participants will be selected by industry organizations, from which most of the nominations will come. Among the committees are: ● the advisory committee for pharmaceutical science and clinical pharmacology, which reviews and evaluates scientific, clinical, and technical issues related to the safety and effectiveness of drug products for use in the treatment of a broad spectrum of human diseases, and ● the pharmacy compounding advisory committee, which provides advice on scientific, technical, and medical issues concerning drug compounding.